title: Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
abstract: OBJECTIVE
  Adjuvant treatment for hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors is associated with increased bone loss depending on the compliance to treatment.
  
  
  METHODS
  In this bone substudy, bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at baseline and after 12- and 24-month treatment in 63 patients receiving Anastrozole as adjuvant treatment for hormone receptor-positive early breast cancer. To minimize the effects of confounders, a matched pair analysis (compliant N = 21, non-compliant N = 21) was performed.
  
  
  RESULTS
  Anastrozole treatment in compliant patients leads to a decrease in BMD (g/cm(2)) at lumbar spine and total hip from baseline to 12 and 24 months (-2.57 % P = 0.004; -2.02 % P = 0.05; -2.57 % P = 0.001 and -4.18 % P = 0.003, respectively) compared to non-compliant patients (-1.71 % P = 0.050; -2.00 % P = 0.085; -1.65 % P = 0.055 and -3.20 % P = 0.005, respectively).
  
  
  CONCLUSIONS
  Anastrozole treatment in compliant patients with breast cancer resulted in a larger, increase in bone loss at 12 and 24 months compared to non-compliant patients. Bone loss stabilized in both groups at the spine from 12- to 24-month treatment, whereas maintained at the total hip.
authors: Department of Gynecology, Gynecological Endocrinology and Oncology, Philipps-University of Marburg, Baldingerstrasse, 35043, Marburg, Germany. kalder@med.uni-marburg.de
authors: Matthias
authors: M
authors: Kalder
authors: Volker
authors: V
authors: Ziller
authors: Ioannis
authors: I
authors: Kyvernitakis
authors: Dana
authors: D
authors: Knöll
authors: Olaf
authors: O
authors: Hars
authors: Peyman
authors: P
authors: Hadji
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced; D010349:Patient Compliance; D017698:Postmenopause; D011987:Receptors, Steroid / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D011987:Receptors, Steroid; D014230:Triazoles; D000077384:Anastrozole